Fr525 BIOSIMILAR SWITCH IN A LARGE QUATERNARY CARE AMERICAN MEDICAL INSTITUTION DOES NOT RESULT IN WORSENING OF INFLAMMATORY BOWEL DISEASE ACTIVITY

Padival, Ruthvik; Qayyum, Farhan M.; Lee, Jeffrey A.; Lam, Simon W.; Heis, Farah; Click, Benjamin; Regueiro, Miguel; Qazi, Taha

doi:10.1016/s0016-5085(21)01546-8

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transition periods are presented for adults, who constituted most of the cohorts. conflicting results from switching to a biosimilar: some reported an increase [40,41], some reported no change [42,43], and one reported a decrease [44]. Our dose escalation result was unexpected considering plasma medication level monitoring: infliximab plasma levels were similar or higher after switching compared with pre-switch levels [30,[45][46][47].…”

Section: Discussionmentioning

confidence: 73%

“…Previous observational studies found similar or decreased use of most health services after switching to infliximab biosimilar. The frequencies of visits to emergency departments and hospitalizations in switchers to biosimilar infliximab were comparable to or lower than those of continuers of the originator product [40,41,[52][53][54]. Concomitant medication use in switchers, including steroids, morphine, and immunosuppressants, was comparable to that of continuers [41,52,55].…”

Section: Discussionmentioning

confidence: 83%

“…The frequencies of visits to emergency departments and hospitalizations in switchers to biosimilar infliximab were comparable to or lower than those of continuers of the originator product [40,41,[52][53][54]. Concomitant medication use in switchers, including steroids, morphine, and immunosuppressants, was comparable to that of continuers [41,52,55]. Our study results were comparable to those of a previous study that found an increased frequency of visits to gastroenterologists-most likely to discuss the switch-in patients with IBDs who switched from originator to biosimilar infliximab [53].…”

Section: Discussionmentioning

confidence: 87%

See 2 more Smart Citations

Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study

Fisher

Kim

Dormuth

2023

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Background. On September 5, 2019, British Columbia announced a new policy (the Biosimilars Initiative) to switch from originator to biosimilar infliximab for patients with inflammatory bowel diseases. Objective. To monitor the impacts of the policy on the use of medications and health services during the first year of the policy. Methods. In this population-based cohort study, we used administrative health data to construct three historical cohorts and one policy cohort of patients with inflammatory bowel diseases who used the originator infliximab. We then monitored the cumulative incidence of medications and health services. Log-likelihood ratios were used to quantify differences between the policy cohort and the average of the historical cohorts. Results. The cohorts included 1839–2368 users of the originator infliximab, ages 4–90 years, mean age 43 years. During the first year of follow-up, we found: (1) a 0.9% increase in the first dispensation of infliximab, biosimilar, or originator; (2) a 16.2% increase in infliximab dose escalation; (3) a decrease of 2.4% in the dispensation of antibiotics and a 2.6% decrease in new use of prednison; (4) an anticipated increase in visits to physicians and gastroenterologists to manage switching to biosimilars (24.0%); (5) a 4.0% decrease in discharges from hospital; and (6) a 2.9% decrease in emergency admissions to hospital. Conclusion. British Columbia’s Biosimilars Initiative for nonmedical switching from originator to biosimilar infliximab for inflammatory bowel diseases was not associated with harmful impacts on medications and health services use. An increase in dose escalation was accompanied by an improvement in health status proxies.

show abstract